Pre-earnings brief
Reports
Mon, Oct 26, 2026
Est. EPS
—
Est. revenue
—
Implied move
±11.6%
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
±10.3%
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases. With a market cap of $11 billion, it plays a crucial role in the healthcare sector, particularly in rare disease treatments.
Last quarter
In Q2 2026, BioMarin reported an EPS of $1.20, significantly beating expectations of $0.79. The stock reacted positively, gaining 2.59% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+104.31%
Avg 1-day reaction
+0.39%
Overall, investors are cautiously optimistic about BioMarin's upcoming earnings, given its recent strong performance. However, there are concerns about potential revenue growth and product sales.
Bull case
If BioMarin can demonstrate strong product sales and continued EPS growth, it could signal robust demand for its therapies and lead to a positive stock reaction.
Bear case
Conversely, if the company fails to meet revenue expectations or shows signs of slowing growth, it could lead to a negative market reaction.
Key metrics to watch
Earnings Per Share (EPS)
$0.85EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.
Revenue Growth
N/AInvestors will look for signs of revenue growth to assess the effectiveness of BioMarin's product pipeline and market demand.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to last quarter's $1.20?
EPS is a crucial metric for assessing profitability, and a significant deviation could impact investor sentiment.
Q2
How are product sales trending compared to previous quarters?
Sales trends will indicate market demand and the effectiveness of BioMarin's strategies, influencing future growth prospects.
Why consensus could be wrong
The Street may be underestimating the potential for BioMarin's product sales to exceed expectations, given recent positive trends in the biotech sector.
Supporting evidence
The company's recent EPS surprises indicate strong operational performance.
Options pricing suggests a higher expected move than historical averages, indicating potential for significant stock movement.
Key risk
If product sales significantly exceed expectations, it could lead to a reevaluation of growth potential.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it reflects BioMarin's ability to maintain momentum in a competitive biotech landscape.
Bull confirmed if
An EPS of $1.00 or higher would confirm strong profitability and investor confidence.
Bear confirmed if
An EPS below $0.70 would raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±9.56%
Historical Avg
±2.1%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±11.6% while BMRN has averaged ±2.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
23.1%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.4%, with a raw directional average of -0.4% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
103.53%
of float
Insider
0.34%
of float
Holders
757
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
20,445,212 sh · $1.1B
10.56%
3.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BioMarin beats expectations, history suggests a potential stock increase of around 0.64%, confirming strong demand for its products.
In line / cautious
If results are in line but management offers cautious commentary, the stock may experience muted movement as investors reassess growth prospects.
Miss
A disappointing earnings report could lead to a decline of approximately 0.37%, as investors react to concerns about future performance.
The lines on the call that would change the story.
Product Sales
N/ASales figures for BioMarin's key products will provide insight into market performance and future revenue potential.
Dodge & Cox Inc.
14,844,930 sh · $819.4M
7.67%
1.9%
Primecap Management Company
14,190,183 sh · $783.3M
7.33%
-0.0%
Vanguard Capital Management LLC
8,743,633 sh · $482.6M
4.52%
1.2%
Vanguard Portfolio Management LLC
8,648,678 sh · $477.4M
4.47%
4.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.